Associations - VHL mutation

VHL mutation VHL mutation	Neuroendocrine Tumor Neuroendocrine Tumor	VHL mutation VHL mutation	Neuroendocrine Tumor Neuroendocrine Tumor	belzutifan Sensitive: A1 - Approval	belzutifan Sensitive: A1 - Approval
VHL mutation VHL mutation	CNS Tumor CNS Tumor	VHL mutation VHL mutation	CNS Tumor CNS Tumor	belzutifan Sensitive: A1 - Approval	belzutifan Sensitive: A1 - Approval
VHL mutation VHL mutation	Renal Cell Carcinoma RCC	VHL mutation VHL mutation	Renal Cell Carcinoma RCC	belzutifan Sensitive: A1 - Approval	belzutifan Sensitive: A1 - Approval
VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	belzutifan Sensitive: C1 - Off-label	belzutifan Sensitive: C1 - Off-label
VHL mutation VHL mutation	Glioblastoma GBM	VHL mutation VHL mutation	Glioblastoma GBM	belzutifan Sensitive: C1 - Off-label	belzutifan Sensitive: C1 - Off-label
VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	PT2385 Sensitive: C2 – Inclusion Criteria	PT2385 Sensitive: C2 – Inclusion Criteria
VHL mutation VHL mutation	Neuroendocrine Tumor Neuroendocrine Tumor	VHL mutation VHL mutation	Neuroendocrine Tumor Neuroendocrine Tumor	PT2385 Sensitive: C3 – Early Trials	PT2385 Sensitive: C3 – Early Trials
VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials	pazopanib Resistant: C3 – Early Trials
VHL mutation VHL mutation	Renal Cell Carcinoma RCC	VHL mutation VHL mutation	Renal Cell Carcinoma RCC	everolimus Sensitive: C3 – Early Trials	everolimus Sensitive: C3 – Early Trials
VHL mutation VHL mutation	Cholangiocarcinoma Cholangiocarcinoma	VHL mutation VHL mutation	Cholangiocarcinoma Cholangiocarcinoma	sunitinib Sensitive: C4 – Case Studies	sunitinib Sensitive: C4 – Case Studies
VHL mutation VHL mutation	Renal Cell Carcinoma RCC	VHL mutation VHL mutation	Renal Cell Carcinoma RCC	doxorubicin hydrochloride Sensitive: D – Preclinical	doxorubicin hydrochloride Sensitive: D – Preclinical